Cited 93 times in

Non-ablative 1550-nm erbium-glass and ablative 10 600-nm carbon dioxide fractional lasers for acne scars: a randomized split-face study with blinded response evaluation.

DC Field Value Language
dc.contributor.author오상호-
dc.contributor.author조성빈-
dc.date.accessioned2015-04-23T16:53:43Z-
dc.date.available2015-04-23T16:53:43Z-
dc.date.issued2010-
dc.identifier.issn0926-9959-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101431-
dc.description.abstractBACKGROUND: Non-ablative 1550-nm erbium-doped fractional photothermolysis systems (FPS) and 10 600-nm carbon dioxide fractional laser systems (CO(2) FS) have been effectively used to treat scars. OBJECTIVE: We compared the efficacy and safety of single-session treatments of FPS and CO(2) FS for acne scars through a randomized, split-face, evaluator-blinded study. METHODS: Eight patients with acne scars were enrolled in this study. Half of each subject's face was treated with FPS and the other half was treated with CO(2) FS. We used a quartile grading scale for evaluations. RESULTS: At 3 months after the treatment, the mean grade of improvement based on clinical assessment was 2.0 +/- 0.5 for FPS and 2.5 +/- 0.8 for CO(2) FS. On each side treated by FPS and CO(2) FS, the mean duration of post-therapy crusting and scaling was 2.3 and 7.4 days respectively and that of post-therapy erythema was 7.5 and 11.5 days respectively. The mean VAS pain score was 3.9 +/- 2.0 with the FPS and 7.0 +/- 2.0 with the CO(2) FS. CONCLUSION: We demonstrated the efficacy and safety of single-session acne scar treatment using FPS and CO(2) FS in East Asian patients. We believe that our study could be used as an essential reference when choosing laser modalities for scar treatment.-
dc.description.statementOfResponsibilityopen-
dc.format.extent921~925-
dc.relation.isPartOfJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAcne Keloid/ethnology-
dc.subject.MESHAcne Keloid/radiotherapy*-
dc.subject.MESHErbium*-
dc.subject.MESHFar East-
dc.subject.MESHHumans-
dc.subject.MESHLasers, Gas/therapeutic use*-
dc.subject.MESHLow-Level Light Therapy/methods*-
dc.subject.MESHMale-
dc.subject.MESHProspective Studies-
dc.subject.MESHSingle-Blind Method-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleNon-ablative 1550-nm erbium-glass and ablative 10 600-nm carbon dioxide fractional lasers for acne scars: a randomized split-face study with blinded response evaluation.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학)-
dc.contributor.googleauthorSB Cho-
dc.contributor.googleauthorSJ Lee-
dc.contributor.googleauthorS Cho-
dc.contributor.googleauthorSH Oh-
dc.contributor.googleauthorWS Chung-
dc.contributor.googleauthorJM Kang-
dc.contributor.googleauthorYK Kim-
dc.contributor.googleauthorDH Kim-
dc.identifier.doi10.1111/j.1468-3083.2009.03551.x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02370-
dc.contributor.localIdA03832-
dc.relation.journalcodeJ01783-
dc.identifier.eissn1468-3083-
dc.identifier.pmid20028443-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/j.1468-3083.2009.03551.x/abstract-
dc.subject.keywordacne scar-
dc.subject.keywordcarbon dioxide-
dc.subject.keyworderbium-glass-
dc.subject.keywordfractional laser-
dc.subject.keywordsplit-face-
dc.contributor.alternativeNameOh, Sang Ho-
dc.contributor.alternativeNameCho, Sung Bin-
dc.contributor.affiliatedAuthorOh, Sang Ho-
dc.contributor.affiliatedAuthorCho, Sung Bin-
dc.citation.volume24-
dc.citation.number8-
dc.citation.startPage921-
dc.citation.endPage925-
dc.identifier.bibliographicCitationJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, Vol.24(8) : 921-925, 2010-
dc.identifier.rimsid51053-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.